Publicaciones científicas
Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis
Jorge Bartolome 1 , Consolacion Molto 2 , Javier David Benitez-Fuentes 3 , Gonzalo Fernandez-Hinojal 4 , Aranzazu Manzano 1 , Pedro Perez-Segura 1 , Abhenil Mittal 2 , Faris Tamimi 2 , Eitan Amir 2 , Alberto Ocana 1
Introduction: Identification of modulators of the immune response with inhibitory properties that could be susceptible for therapeutic intervention is a key goal in cancer research. An example is the human leukocyte antigen G (HLA-G), a nonclassical major histocompatibility complex (MHC) class I molecule, involved in cancer progression.
Methods: In this article we performed a systematic review and meta-analysis on the association between HLA-G expression and outcome in solid tumors. This study was performed in accordance with PRISMA guidelines and registered in PROSPERO.
Results: A total of 25 studies met the inclusion criteria. These studies comprised data from 4871 patients reporting overall survival (OS), and 961 patients, reporting disease free survival (DFS). HLA-G expression was associated with worse OS (HR 2.09, 95% CI = 1.67 to 2.63; P < .001), that was higher in gastric (HR = 3.40; 95% CI = 1.64 to 7.03), pancreatic (HR = 1.72; 95% CI = 0.79 to 3.74) and colorectal (HR = 1.55; 95% CI = 1.16 to 2.07) cancer. No significant differences were observed between the most commonly utilized antibody (4H84) and other methods of detection. HLA-G expression was associated with DFS which approached but did not meet statistical significance.
Discussion: In summary, we describe the first meta-analysis associating HLA-G expression and worse survival in a variety of solid tumors.
Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022311973.
CITA DEL ARTÍCULO Front Immunol. 2023 May 18:14:1165813. doi: 10.3389/fimmu.2023.1165813. eCollection 2023.
Nuestros autores
